Edwards Lifesciences Corp
EW
Market Cap$51.26B
Close$
Earnings Call Q4 2023
February 6, 2024 - AI Summary
Edwards Lifesciences reported strong financial performance in 2023, with full-year sales up 12% to $6 billion.
The company achieved better-than-expected Q4 growth of 13%, driven by a broad portfolio of innovative therapies.
In TAVR, the company experienced strong adoption of its SAPIEN 3 Ultra RESILIA platform and completed enrollment in the PROGRESS trial ahead of schedule. They also expect to present data from the EARLY TAVR trial later this year.
Exclusive for Stockcircle Pro members
Sign up
$40.57
52.3% downside
Current Fair Value
52.3% downsideOvervalued by 52.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $51.26 Billion |
|---|---|
| Enterprise Value | $50.16 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $2.33 |
| Beta | 1.0 |
| Outstanding Shares | 602,600,000 |
| Avg 30 Day Volume | 3,045,777 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 36.25 |
|---|---|
| PEG | 1082.88 |
| Price to Sales | 8.51 |
| Price to Book Ratio | 7.73 |
| Enterprise Value to Revenue | 8.16 |
| Enterprise Value to EBIT | 28.94 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
ESG Score
No data
About Edwards Lifesciences Corp
CEO: Michael Mussallem